Harnessing the immune system to treat Ewing sarcoma in the lungs
Dr Jonathan Fisher aims to create an 'off the shelf' version of immunotherapy to for hard-to-treat Ewing sarcoma.
We have been funding expert research since 2016, aiming to ensure that every child and young person has a safe and effective treatment for their cancer, and that they can live long and happy lives post-treatment.
Dr Jonathan Fisher aims to create an 'off the shelf' version of immunotherapy to for hard-to-treat Ewing sarcoma.
Dr Olivier Pardo will investigate how osteosarcoma cells which escape into the bloodstream survive to spread elsewhere in the body.
How the 3D shape of fusion gene genetic code affects cancer cell behaviour and whether shape-modifying medicines could mitigate these effects.
Assessing rhabdomyosarcoma risk prediction markers based on the biological conditions in the tumour, like low oxygen levels, few blood vessels, and genetics.
Looking at why ALCL sometimes relapses with a new targeted treatment, and understanding how to optimise this treatment approach.
Looking at the differences between healthy brain cells before and after treatment to uncover the mechanisms behind brain-related late effects.
Finding a way to identify patients at risk of brain related side effects from leukaemia treatment, and gathering data to inform future treatment options.
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.
Developing a test that can measure the amount of chemotherapy-resistant leukaemia cells in patient's blood samples. This would provide the foundations for future research.